SWK Holdings Corporation (SWKH) Market Cap
SWK Holdings Corporation has a market capitalization of $192.3M.
Financials based on reported quarter end 2025-12-31
Price: $15.90
▲ 0.00 (-4.96%)
Market Cap: 192.33M
NASDAQ · time unavailable
CEO: Jody. D Staggs
Sector: Financial Services
Industry: Asset Management
IPO Date: 1999-09-23
Website: https://www.swkhold.com
SWK Holdings Corporation (SWKH) - Company Information
Market Cap: 192.33M · Sector: Financial Services
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
Analyst Sentiment
Based on 1 ratings
Consensus Price Target
No data available
Price & Moving Averages
Related Companies in Financial Services
CONSUMER PORTFOLIO SERVICES INC (CPSS)
Financial Services
$0.19B
Mkt Cap
CF BANKSHARES INC (CFBK)
Financial Services
$0.19B
Mkt Cap
CITIZENS COMMUNITY BANCORP INC (CZWI)
Financial Services
$0.20B
Mkt Cap
UNITED SECURITY BANCSHARES (UBFO)
Financial Services
$0.19B
Mkt Cap
FIRST INTERNET BANCORP (INBK)
Financial Services
$0.20B
Mkt Cap
CPI CARD GROUP INC (PMTS)
Financial Services
$0.20B
Mkt Cap
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"SWK Holdings (SWKH) reported revenue of ~$8.0M for the quarter ended 2025-12-31, with net income of -$19.4M and EPS of -$1.59 (net margin about -242%). Cash generation was positive: operating cash flow was ~$19.0M and free cash flow (FCF) was ~$19.1M, supported by the period’s working-capital dynamics, despite the accounting loss. On the balance sheet, total assets were ~$272.4M versus total liabilities of ~$37.3M, leaving equity of ~$235.1M. Net debt was -$10.7M, indicating net cash. For shareholder returns, the stock price rose ~24.7% over the last year (with ~15.7% over 6 months), providing meaningful capital appreciation. Dividends appear minimal/one-off in the provided data (dividends paid: $0), and buybacks were not provided, so total return is likely driven primarily by price performance rather than distributions. Valuation metrics such as P/E, FCF yield, and analyst targets were not provided; with earnings currently negative, traditional earnings-based valuation is less informative. Overall, profitability is weak on an accounting basis, but cash flow and balance-sheet strength support financial resilience."
Revenue Growth
Only a single-period revenue figure ($8.0M) is provided, limiting assessment of YoY/quarterly growth. Performance is therefore evaluated as neutral due to lack of trend context.
Profitability
Net income was -$19.4M with EPS of -$1.59. Net margin is approximately -242%, indicating significantly weak profitability in the most recent period.
Cash Flow Quality
Despite the accounting loss, operating cash flow was ~$19.0M and FCF was ~$19.1M. This suggests cash generation is currently positive, though the sustainability of the drivers isn’t assessable from limited history.
Leverage & Balance Sheet
Financial resilience looks strong: net debt is -$10.7M (net cash), with equity of ~$235.1M against liabilities of ~$37.3M. Leverage risk appears relatively low based on provided figures.
Shareholder Returns
Total shareholder value creation is likely led by capital appreciation (1-year price change: +24.7%). Dividends paid were $0 in the quarter provided, and buybacks were not disclosed, so returns are not distribution-driven.
Analyst Sentiment & Valuation
Valuation metrics (P/E, FCF yield) and analyst price targets were not provided. With negative earnings, earnings-based valuation is not meaningful from the available dataset.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Management sounded confident on the quarter—calling Q2 earnings a reasonable run-rate and emphasizing business simplification and shareholder returns ($4/share dividend; $49M distributed; additional $3M buybacks YTD). However, the Q&A revealed real operational and portfolio pressure points. Near-term FDA/regulatory change risk is treated as limited for direct portfolio exposures (no pending approvals), and pricing risk is largely dismissed with specific examples (Eton, Ocufer/Shield, Journey). The more candid hurdle is NIA scientific funding cuts: vendors in that channel reportedly lost orders, with management calling the broader ecosystem been in a tough cycle for years. In parallel, the competitive private credit backdrop is acknowledged as increasing willingness of less-suitable entrants to deploy capital, driving SWK’s measured deployment pace and reliance on adding to existing performing borrowers rather than chasing new risk. Third-quarter results were flagged as 'messy' due to MOD3 transition mechanics under a TSA through mid-September, though costs are reimbursed.
Growth Catalysts
- Sale of majority of royalty assets and MOD3 subsidiary assets (completed around book value; premium to SWK’s historical trading levels)
- Ongoing earnings run-rate characterization: management called Q2 results a reasonable proxy for forward earnings power
Business Development
- Aptar Group exercised option to acquire majority of MOD3 assets on July 15, 2025 for a predetermined purchase price of $6.9 million (including $3.3 million already received)
- MOD3 transition services agreement (TSA) with Aptar through mid-September (implies temporary operational involvement by SWK with costs reimbursed)
Financial Highlights
- GAAP pretax net income: $4.6 million or $0.37 per diluted share in Q2 2025
- GAAP book value per share: $20.23 (down 11% YoY vs. $22.72); adjusted for $4 per share dividend, GAAP book value per share: $24.46 (+6.8% YoY)
- Non-GAAP adjusted net income and finance segment adjusted non-GAAP net income: $4.6 million total (management-stated run rate for the business going forward)
- Finance receivables segment revenue decline: $1.2 million YoY decrease driven by $3.4 million decrease in interest and fees due to paydowns/payoffs and sale of majority of royalty portfolio (partially offset by $0.2 million increase from add-on fundings/newly funded finance receivables)
- Operating expenses: $5.4 million in Q2 2025 vs $5.4 million baseline described as 9.9%? (transcript indicates 'compared to 9.9% in Q2 2024'—the explicit prior-year expense figure is not consistently stated in dollars); MOD3 operating expenses: $1.2 million vs $2.5 million prior year quarter; finance receivables segment operating expenses: $4.2 million vs $7.4 million prior year quarter
- Provision for credit losses driver: $800,000 in Q2 2025 vs $4.1 million in Q2 2024; primarily due to $500,000 of asset impairments in Q2 2025 vs $4.3 million of asset impairments in Q2 2024
- Shareholder returns: $49 million returned via $4 per share dividend during Q2; year-to-date $3 million returned via repurchase of ~200,000 shares
Capital Funding
- Dividend: $4 per share (Q2 proceeds distributions total stated as $49 million)
- Share repurchases: just under 60,000 shares for $0.9 million during the quarter; plus post-quarter repurchase of ~8,000 shares for total cost $1.3 million
- Remaining financial assets summary (operating capital structure characterization): $234 million gross performing first lien term loans with 14.1% effective yield; $5 million public equities warrants; 11 private warrants/earnouts carried at $0 GAAP; general loan loss reserve: $8.8 million
Strategy & Ops
- Business simplification via asset sales: completed sale of majority of royalty assets; completed sale of majority of MOD3 assets
- Third quarter operational noise expected due to MOD3 exiting the ecosystem; costs reimbursed under transition services agreement through mid-September
- Management stated normalized SG&A target: look-through of Q2 suggests normalized SG&A ~ $2.0 million (Q2 included legal spend; normalized goal level emphasized)
Market Outlook
- Near-term regulatory expectation (management framing): fewer drugs approved could occur, but management stated it likely does not impact SWK’s portfolio because no drug/device companies are pending approved products
Risks & Headwinds
- Regulatory/tariff backdrop: initial discussion included tariffs; management reported reviewing portfolio companies and believing 'minimal exposure' (no quantified exposure provided)
- Regulatory change risk: FDA-related uncertainty; near term could mean fewer drugs approved, but SWK stated no direct pending approval exposure in its portfolio
- Pricing risk risk-category: management believes borrowers are 'not too at risk'; examples: Eton rare disease pricing structure; Ocufer Shield low-priced product with limited concern about rebates/negotiations; Journey dermatology largely cash pay
- Scientific funding cuts (NIA): identified as the area of more concern—SWK has a couple of companies that are vendors into the channel (one CDMO and a life science tools seller); management said they 'lost some orders' and believes the space has had a tough run over the last couple of years (not characterized as drastic/material to SWK as a lender)
- Private credit competition / risk appetite: management noted increased capital availability and entrants (including interval funds and private BDCs) that 'need to deploy capital'; SWK response was 'tempered' deployment pace due to cost of capital and discipline
Sentiment: MIXED
Note: This summary was synthesized by AI from the SWKH Q2 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.